# Duration of Dual Anti-Platelet Therapy (DUAL-ACS)

Study · id `cardio:ct-nct03252249` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03252249](<https://clinicaltrials.gov/study/NCT03252249>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT03252249

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 5094 participants.

## Technical summary

Registry record NCT03252249. Randomized; no masking; primary purpose treatment. Start 2018-04-26 (actual); primary completion 2023-02-04 (actual). Results posted on 2026-01-28.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 5094 participants (enrolled count; ClinicalTrials.gov record NCT03252249, source copy `cardio:ctgov-nct03252249-2026-11-03`, retrieved 2026-11-18)
- Started: 2018-04-26 (actual) (ClinicalTrials.gov record NCT03252249, source copy `cardio:ctgov-nct03252249-2026-11-03`, retrieved 2026-11-18)
- Primary completion: 2023-02-04 (actual) (ClinicalTrials.gov record NCT03252249, source copy `cardio:ctgov-nct03252249-2026-11-03`, retrieved 2026-11-18)
- Completion: 2023-02-04 (actual) (ClinicalTrials.gov record NCT03252249, source copy `cardio:ctgov-nct03252249-2026-11-03`, retrieved 2026-11-18)
- Results first posted: 2026-01-28 (ClinicalTrials.gov record NCT03252249, source copy `cardio:ctgov-nct03252249-2026-11-03`, retrieved 2026-11-18)
- Countries: New Zealand; United Kingdom (ClinicalTrials.gov record NCT03252249, source copy `cardio:ctgov-nct03252249-2026-11-03`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03252249-2026-11-03`, retrieved 2026-11-18)

## The registry's words

- Brief title: Duration of Dual Anti-Platelet Therapy (DUAL-ACS)
- Condition: Acute Coronary Syndrome
- Condition: Coronary Artery Disease
- Intervention (Other): 3 months dual anti-platelet therapy
- Intervention (Other): 12 months dual anti-platelet therapy
- Lead sponsor: University of Edinburgh
- Lead sponsor class: OTHER
- Collaborator: British Heart Foundation
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: University of Edinburgh (`cardio:org-university-of-edinburgh`)
- Registry lists this organization as a collaborator: British Heart Foundation (`cardio:org-british-heart-foundation`)

## Provenance

Content hash: 41d15b96eb859c87a8c26f402e61af69cc93662d1147a847e83109ccafee4630
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
